Irvine-based Allergan Inc. said Tuesday that it signed two development deals with Molecular Partners AG of Zurich for eye disease treatments.
Allergan will pay Molecular $62.5 million in combined upfront payments under the agreements. Terms also provide for possible additional payments of up to $1.4 billion, based on future milestones.
Allergan and privately held Molecular are working on developing biologic products for treating wet age-related macular degeneration. Age-related macular degeneration is a leading cause of blindness.
One deal is an exclusive license agreement for the design, development and commercialization of a therapy for wet age-related macular degeneration. The other agreement is a discovery alliance, in which Allergan and Molecular will design and develop proteins to fight selected targets implicated in serious eye diseases.
